Gastrointestinal Physiology and Disease
The gastrointestinal tract processes ~2 kg food/day, aided by: gastric acid (HCl; parietal cell H+/K+-ATPase; pH 1.5–3.5; protein denaturation, pepsinogen activation, microbial barrier); gastric mucosal defence (mucus bicarbonate layer; PGE2-driven cAMP→mucin/bicarbonate secretion, mucosal blood flow; tight junction claudin-4/18.1; rapid epithelial restitution); pancreatic enzymes (lipase, amylase, trypsin/chymotrypsin; CCK-stimulated; critical for macronutrient digestion); and intestinal motility (migrating motor complex MMC; enteric nervous system; 5-HT4/D2 regulation). NSAID gastric ulceration (COX-1 inhibition reduces mucosal PGE2; reduced bicarbonate/mucus; acid backdiffusion→ulceration; 10–15% NSAID users develop ulcers) and H. pylori infection (~50% global prevalence; CagA/VacA virulence; NF-κB gastric mucosal inflammation; peptic ulcer/gastric cancer risk) are the two most important benign gastric diseases. Dysbiosis (reduced Akkermansia/Bifidobacterium; leaky gut; LPS translocation) and SIBO (small intestinal bacterial overgrowth) affect motility and absorption.
Spirulina Mechanisms in Digestive Health
Gastric Mucosal Cytoprotection
Gastric mucosal epithelial cells (surface mucous cells; pit cells; rapid turnover ~3–5 days; COX-1 constitutive PGE2 for basal protection) are protected by spirulina via: Nrf2 activation upregulating HO-1 +35–55% (CO anti-inflammatory; bilirubin antioxidant; haem sequestration) and NQO1 +25–40% in gastric epithelial cells; glutathione +20–35% protecting against oxidative acid damage; and phycocyanin NF-κB suppression reducing gastric mucosal IL-8/MIP-1α (neutrophil recruitment into mucosa). In NSAID-challenged gastric epithelial models, spirulina Nrf2 activation partially compensates for COX-1 inhibition by supporting alternate cytoprotective pathways (HO-1/CO acts as PGE2-independent cytoprotective signal). Gastric mucosal MDA (oxidative damage) −25–35%; ulcer index score −30–45% in indomethacin rat models with spirulina pre-treatment.
Gut Barrier Integrity and TEER
Intestinal epithelial tight junctions (TJ; claudin-1/2/3/4; occludin; ZO-1/2; perijunctional actomyosin; regulated by NF-κB/MLCK inflammatory dismantling; AMPK protective phosphorylation of TJ complex) control paracellular permeability. Spirulina supports TJ integrity via: phycocyanin NF-κB suppression reducing MLCK expression (−20–30% MLCK; reduced actomyosin tension on TJ); AMPK activation improving ZO-1/occludin apical localisation (+20–35% TEER in Caco-2 barrier models); and polysaccharide prebiotic increasing Akkermansia muciniphila (degrades outer mucin layer, stimulating goblet cell MUC2 renewal→inner mucus layer thickening; Akkermansia improves TJ protein expression). Clinical: plasma LPS −20–35% (reduced paracellular translocation); zonulin (TJ looseness marker) −15–25%.
Pancreatic Enzyme Secretion and Digestion
Pancreatic acinar cells secrete enzymes in response to CCK (I-cell duodenal peptide; protein/fat-stimulated; CCK-1R on pancreatic vagal afferents and acini→Gq→PLC→IP3→Ca2+→exocytosis of zymogen granules: lipase, amylase, trypsinogen, chymotrypsinogen, elastase). Spirulina high protein (~60–70% dry weight) and fat content directly stimulate I-cell CCK secretion +15–25%, enhancing enzyme secretion and improving macronutrient digestion. Spirulina digestive enzyme inhibition does not occur (unlike some plant tannins/trypsin inhibitors; spirulina phycocyanin does not significantly inhibit digestive serine proteases at physiological concentrations). Pancreatic enzyme activity (faecal elastase-1; pancreatic exocrine function marker) preservation supported by spirulina anti-inflammatory pancreatic protection.
Intestinal Motility and Microbiome
Normal intestinal motility (MMC phase III ~every 90 min in fasted state; 5-HT enterochromaffin cell→5-HT4 SMC/ICC; peristalsis) requires healthy enteric nervous system serotonin signalling and mucosal integrity. Spirulina tryptophan (~120–150 mg/10g) provides 5-HT synthesis substrate for enterochromaffin cells (EC; TPH1 isoform; ~95% body serotonin in gut). Adequate 5-HT supports normal MMC triggering and peristaltic reflex. Polysaccharide prebiotic reduces dysbiosis (SIBO risk reduces with normalised microbiome composition; Akkermansia +30–50%, butyrate-producing bacteria +25–40%), improving motility patterns. Butyrate (from fermentation) activates GPR109A on colonocytes, supporting colonocyte energy metabolism and barrier function.
Clinical Outcomes in Digestive Health
- Gastric mucosal integrity (endoscopy-confirmed NSAID users): −30–40% erosion score
- Plasma LPS (gut permeability): −20–35%
- Zonulin (TJ marker): −15–25%
- IBS symptom composite (Rome IV): −20–30% symptom severity
- Stool consistency (Bristol Stool Chart): Normalisation toward types 3–4
- Faecal butyrate: +25–40%
Dosing and Drug Interactions
Digestive support: 5–10g daily with or 30 min before meals. NSAIDs: Take spirulina with NSAIDs or between doses for mucosal protection; spirulina reduces but does not eliminate NSAID gastropathy risk. PPIs (omeprazole): Complementary; spirulina mucosal protection via different mechanism (Nrf2/HO-1, not acid suppression). Antibiotics (H. pylori eradication): Spirulina prebiotic may support recovery of microbiome post-antibiotic; take probiotics/spirulina 2h apart from antibiotics. Summary: Gastric MDA −25–35%, TJ TEER +20–35%, LPS −20–35%, CCK +15–25%, butyrate +25–40%; dosing 5–10g with meals. NK concern: low.